PD-L1 Targeting Molecular Imaging of Solid Tumors

Gastrointestinal Tumors Clinical Trial

Official title:

PD-L1 Targeting Molecular Imaging of Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04629326
• Other study ID #: WL12-Tumor
• Status: Recruiting
• Phase: N/A
• Start date: July 20, 2021
• Est. completion date: November 2024

Study information

• Verified date: January 2024
• Source: Peking University Cancer Hospital & Institute
• Contact: Hua Zhu
• Phone: 010-88196495
• Email: zhuhuabch[@]pku.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the study is to constrcut a noninvasive approach WL12 PET/CT to detect the PD-L1 expression of tumor lesions in patients with gastrointestinal tumors and to identify patients benefiting from anti-PD-1/L1 treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: November 2024
• Est. primary completion date: November 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 1. Aged >18 years old; ECOG 0 or 1;

• 2. Patients with Gastrointestinal tumors;

• 3. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);

• 4. life expectancy >=12 weeks.

Exclusion Criteria:

• 1. Significant hepatic or renal dysfunction;

• 2. Is pregnant or ready to pregnant;

• 3. Cannot keep their states for half an hour;

• 4. Refusal to join the clinical study;

• 5. Suffering from claustrophobia or other mental diseases;

• 6. Any other situation that researchers think it is not suitable to participate in the experiment.

Related Conditions & MeSH terms

• Digestive System Neoplasms
• Gastrointestinal Neoplasms
• Gastrointestinal Tumors

Intervention

Other:
• 68Ga-WL12 PET/CT
WL12, labeled with PET radio-nuclide ( Ga-68 )will be used as a molecular imaging tracer for PET/CT scanning

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking University Cancer Hospital & Institute

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Standardized uptake value(SUV)	The uptake of the tracer in the primary and metastatic tumor lesions by measuring standardized uptake value(SUV)on PET/CT	2 years